| Price | 158.00p on 24-06-2026 at 07:03:34 |
|---|---|
| Change | 0.00p 0% |
| Buy | 157.00p |
| Sell | 155.00p |
| Last Trade: | Buy 2,705.00 at 158.00p |
| Day's Volume: | 0 |
| Last Close: | 158.00p |
| Open: | 158.00p |
| ISIN: | KYG4672N1198 |
| Day's Range | 0.00p - 0.00p |
| 52wk Range: | 153.00p - 292.00p |
| Market Capitalisation: | £1.36b |
| VWAP: | 0.00p |
| Shares in Issue: | 859.75m |
Sector: Medicine and Biotech
Listed In: FTSE AIM 100, FTSE AIM All-Share,
Hutchmed (HCM) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 2,705 | 158.00p | Suspected BUY Trade |
16:35:28 - 23-Jun-26 |
| Sell* | 22 | 155.00p | Automatic Execution |
16:24:54 - 23-Jun-26 |
| Sell* | 84 | 155.00p | Automatic Execution |
16:24:54 - 23-Jun-26 |
| Buy* | 69 | 155.50p | Automatic Execution |
16:24:54 - 23-Jun-26 |
| Unknown* | 0 | 155.50p | SI Trade |
16:22:59 - 23-Jun-26 |
| Sell* | 5,000 | 155.00p | Automatic Execution |
16:22:59 - 23-Jun-26 |
| Sell* | 7,000 | 155.00p | Automatic Execution |
16:22:59 - 23-Jun-26 |
| Buy* | 645 | 156.00p | Automatic Execution |
15:21:01 - 23-Jun-26 |
| Buy* | 6 | 155.97p | Ordinary |
15:14:09 - 23-Jun-26 |
| Buy* | 4,804 | 155.959p | Ordinary |
14:54:27 - 23-Jun-26 |
Hutchmed (HCM) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 12th Jun 2026 7:00 am | RNS-R | HUTCHMED Highlights Sovleplenib Phase III Data |
| 5th Jun 2026 9:30 am | RNS | Block Admission Application |
| 22nd May 2026 7:00 am | RNS-R | HUTCHMED Highlights Data to be Presented at ASCO |
| 21st May 2026 11:00 am | RNS-R | NMPA approval for ELUNATE with TYVYT |
| 12th May 2026 12:45 pm | RNS | Announcement on Results of Annual General Meeting |
| 30th Apr 2026 9:30 am | RNS | Total Voting Rights |
| 29th Apr 2026 11:00 am | RNS-R | HUTCHMED Announces NDA Acceptance in China |
| 9th Apr 2026 9:30 am | RNS | 2025 Annual Report and Notice of AGM |
| 9th Apr 2026 7:00 am | RNS-R | Data to be Presented at AACR Annual Meeting 2026 |
| 23rd Mar 2026 7:00 am | RNS-R | HUTCHMED Initiates Phase III Trial of HMPL-760 |
